What were the results of Pfizer's weight loss jab trial?

In a mid-stage clinical trial, adults with obesity lost up to 12.3 percent of their body weight after 28 weeks on Pfizer's experimental monthly injection, PF-08653944.

What are the side effects of Pfizer's PF-08653944 drug?

Side effects of PF-08653944 were predominantly mild or moderate, similar to other drugs on the market.

Which other companies are developing weight loss drugs like Pfizer's?

Companies such as Amgen, Eli Lilly, and Novo Nordisk are also developing weight loss therapies, including injections and pills.

Home / Health / Pfizer's Monthly Jab: 12.3% Weight Loss Seen

Pfizer's Monthly Jab: 12.3% Weight Loss Seen

5 Feb

•

Summary

Pfizer's new drug helped people lose up to 12.3% body weight.
The monthly injection showed mild to moderate side effects.
Competitors like Eli Lilly and Novo Nordisk are also active in this market.

Pfizer's Monthly Jab: 12.3% Weight Loss Seen

Pfizer announced Tuesday positive results from a mid-stage clinical trial for its monthly weight loss injection, PF-08653944. Adults with obesity administered the drug lost up to 12.3 percent of their body weight compared to a placebo over 28 weeks.

The trial indicated no plateau in weight loss by week 28, suggesting continued loss through the study's conclusion. Pfizer's CEO noted the drug's competitive profile in tolerability and efficacy, with side effects being primarily mild to moderate.

Developed by Metsera, which Pfizer acquired last year, the drug showed a promising monthly dosing regimen. Pfizer plans to advance a higher dose into Phase 3 trials based on these findings.